Glaxo takes $2.4 bln charge, Avandia mostly settled
LONDON (Reuters) - GlaxoSmithKline (GSK.L) expects to record a legal charge of 1.57 billion pounds ($2.4 billion) for the second quarter after settling the "substantial majority" of claims relating to its controversial diabetes pill Avandia.
The move, designed to clear the decks of outstanding legal issues, will wipe out most of the drugmaker's expected earnings for the three months to June but leaves it better placed to grow profits in future.
The British drugmaker said on Thursday the charge would cover not only settlements for Avandia but also other long-standing legal cases, including an investigation into its former factory at Cidra in Puerto Rico, and anti-trust and product liability litigation over antidepressant Paxil.
The charge will cost 1.35 billion pounds after tax.
News of the hefty charge -- equal to about 2.5 percent of Glaxo's market value -- initially dampened an anticipated rally in the shares after a U.S. panel voted to keep Avandia on the market with new warnings on heart risks.
However, the stock gained ground in morning trade and was up 2.2 percent by 1200 GMT, outperforming a 0.8 percent advance in the European drugs sector .SXDP.
"Some people might baulk at the size of the charge but probably most will say this is putting it all behind the company, so we can now look to the continuing business and view the stock on a more rational basis," said Deutsche Bank analyst Mark Clark.
The big legal hit will slash second-quarter earnings per share by more than 26 pence, according to analysts, wiping out most of the group's profit for the period. Prior to the news, the consensus EPS forecast had been 29.5 pence, according to Thomson Reuters data. Glaxo will report results on July 21.
"It is a negative in the short term but longer term it is a positive because from here we anticipate that EBIT (earnings before interest and tax) will actually go up 2 to 5 percent based on the company running these charges through now," said UBS analyst Gbola Amusa.
"They are closing the book on uncertainties upfront, which makes for a cleaner organization."
Morgan Stanley analyst Andrew Baum said he anticipated renewed interest in the shares from yield-hungry British investors, given the expected dividend yield of 5.3 percent in 2010.
FALLING AVANDIA SALES
Glaxo did not specify the amount it was setting aside to settle liability claims over Avandia, arguing settlement terms were confidential.
Initially, analysts had feared it might have to spend as much as $6 billion to resolve an estimated 13,000 U.S. Avandia claims. But the favorable panel vote and recent reports of modest settlements means some now see a bill of around $1 billion or less.
Avandia was once Glaxo's second-biggest drug, with sales of around $3 billion a year. Since 2007, however, it has been in decline after it was first linked to heart attacks. It sold just $1.2 billion in 2009.
Those sales are expected to keep falling as new restrictions on its use are introduced, with the U.S. Food and Drug Administration expected to follow the panel's recommendations. But investor concerns have been focused more on the company's legal liability than on the relatively modest impact of Avandia to the sales and profit lines.
Glaxo said the resolution of the various disputes was a significant step in clearing legal uncertainties.
"This represents a substantial proportion of GSK's outstanding litigation. This progress is helping us to reduce financial uncertainty and risk for shareholders," Dan Troy, the drugmaker's general counsel, said in a statement.
While it did not break out the other components of the charge, Glaxo did disclose that the agreement in principle relating to quality problems at the Cidra plant was for a total of 500 million pounds, leaving 1.07 billion to cover claims for Paxil, Avandia and other products.
A company spokeswoman said the latest 1.57 billion pounds charge would be in addition to the company's current balance sheet legal provision of 2.3 billion pounds.
Avandia also faces scrutiny from the European Medicines Agency, which has launched a new review into the drug's risks and benefits and will discuss the matter July 19-22 in London.
(Editing by Dan Lalor and Michael Shields)
($1 = 0.6580 pound)
- Sierra Leone's chief Ebola doctor contracts the virus
- Exclusive: Ukraine rebel commander acknowledges fighters had BUK missile
- Gaza bloodshed deepens as airlines shun Israel |
- TransAsia Airways plane crashes in typhoon-hit Taiwan, killing 47 |
- South Korea ferry fugitive hid behind cabin wall, bags of cash at hand